Sa Sa International Q1 Revenue Jumps 24% as Hong Kong Equities Show Mixed RecoveryGlobal Report·Aug 7 at 09:18 AM03788+6.53%02166+0.76%
SystImmune Announces Second Approval of Iza-bren in China for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell CarcinomaUnusual Whales·Jul 17 at 12:27 PM688506+1.33%02615
Mobile’s Cash Flow Surges 128% as Gome Resorts to Share Issuance for Debt SurvivalGlobal Report·Jul 7 at 10:38 AM00951-0.85%00788+1.09%
15:07 ETSystImmune Announces First Approval of Iza-bren for the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma in Chinaprnewswire·Jun 22 at 07:09 PM688506+1.33%02615
Bristol Myers says ADC licensed from China hits mark in aggressive breast cancerbiopharmadive·Feb 27 at 01:55 AM688506+1.33%02615
Biokin Pharmaceutical T-Bren (HER2 ADC) demonstrates best-in-class potential, revealing efficacy data for treated HER2 mutated NSCLC for the first time, with a 12-month PFS rate of 73.5%Wallstreetcn·Dec 7, 2025 at 10:48 AM02615688506+1.33%
【New Stock Listing】BIOKIN (2615) subscription entry fee is 39,293 yuan, and 5 funds including the US-listed pharmaceutical company BMS are invested in the stocketnet·Nov 6, 2025 at 11:59 PM02615
